Repros' Proellex sees strong Ph II data

The USA's Repros Therapeutics has reported positive results from an interim analysis of a US Phase II endometriosis trial. The study was designed to assess the effect of Proellex, a progesterone receptor modulator, on symptom control in women with the common condition, characterized by growth of endometrial tissue outside the uterus who have moderately severe to severe pain.

According to the firm, the data show that pain, the most troublesome symptom associated with the womb condition, is statistically and clinically meaningfully reduced in one to two months of treatment compared with placebo.

These results clearly confirm and extend the positive results that were obtained from the initial proof-of-concept study done in Europe 18 months ago, Repros noted. In that study relief of pain was also rapid and sustained but most pronounced with the Proellex 50mg dose which was superior to the active control Takeda/Abbott Laboratories' oncology treatment Lupron (leuprolide acetate).